Tirabrutinib + Tirabrutinib + Tirabrutinib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory Primary Central Nervous System Lymphoma
Conditions
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Trial Timeline
Dec 29, 2021 → Mar 31, 2027
NCT ID
NCT04947319About Tirabrutinib + Tirabrutinib + Tirabrutinib
Tirabrutinib + Tirabrutinib + Tirabrutinib is a phase 2 stage product being developed by Ono Pharmaceutical for Refractory Primary Central Nervous System Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT04947319. Target conditions include Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Primary Central Nervous System Lymphoma were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04947319 | Phase 2 | Active |
Competing Products
20 competing products in Refractory Primary Central Nervous System Lymphoma